Robert Blanks

Robert Blanks

General Counsel at ARDELYX, INC.

Net worth: 3 M $ as of 30/03/2024

64 year
Health Technology
Consumer Services

Profile

Robert C.
Blanks
is the founder of Phaedrus Pharmaceuticals, which was founded in 1999.
He held the title of Vice President-Technical Operations from 1999 to 2003.
Mr. Blanks's current job is as Chief Regulatory Affairs Officer at Ardelyx, Inc., starting in 2013.
Mr. Blanks's former jobs include being a Senior Director-Quality Affairs at GelTex Pharmaceuticals, Inc., a Vice President-Quality at Idenix Pharmaceuticals LLC from 2006 to 2009, a Vice President-Chemistry, Manufacturing & Control at Flexion Therapeutics, Inc. from 2009 to 2012, and a Vice President-Operations at Trine Pharmaceuticals, Inc. from 2003 to 2008.
Mr. Blanks's education includes a graduate degree from Boston College and an undergraduate degree from Bowdoin College.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
14/03/2024 367,186 ( 0.16% ) 3 M $ 30/03/2024

Robert Blanks active positions

CompaniesPositionStart
ARDELYX, INC. General Counsel 31/07/2013
All active positions of Robert Blanks

Former positions of Robert Blanks

CompaniesPositionEnd
FLEXION THERAPEUTICS, INC. Corporate Officer/Principal 31/10/2012
IDENIX PHARMACEUTICALS INC Corporate Officer/Principal 31/07/2009
Corporate Officer/Principal 18/09/2008
Phaedrus Pharmaceuticals Founder 28/02/2003
Corporate Officer/Principal -
See the detail of Robert Blanks's experience

Training of Robert Blanks

Boston College Graduate Degree
Bowdoin College Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Robert Blanks's experience

Connections

64

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
ARDELYX, INC.

Health Technology

Private companies5

Health Technology

Health Technology

Health Technology

Health Technology

Phaedrus Pharmaceuticals

See company connections